Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review...

Descripción completa

Detalles Bibliográficos
Autores principales: Villa, Federica, Crippa, Alessandra, Pelizzoni, Davide, Ardizzoia, Alessandra, Scartabellati, Giulia, Corbetta, Cristina, Cipriani, Eleonora, Lavitrano, Marialuisa, Ardizzoia, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/
https://www.ncbi.nlm.nih.gov/pubmed/37833875
http://dx.doi.org/10.3390/ijms241914427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/
https://www.ncbi.nlm.nih.gov/pubmed/37833875
http://dx.doi.org/10.3390/ijms241914427

Ejemplares similares